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Background: Medulloblastomas, the most frequent malignant brain tumours affecting children, comprise at least 4
distinct clinicogenetic subgroups. Aberrant sonic hedgehog (SHH) signalling is observed in approximately 25% of
tumours and defines one subgroup. Although alterations in SHH pathway genes (e.g. PTCH1, SUFU) are observed in
many of these tumours, high throughput genomic analyses have identified few other recurring mutations. Here, we
have mutagenised the Ptch+/- murine tumour model using the Sleeping Beauty transposon system to identify
additional genes and pathways involved in SHH subgroup medulloblastoma development.
Results: Mutagenesis significantly increased medulloblastoma frequency and identified 17 candidate cancer genes,
including orthologs of genes somatically mutated (PTEN, CREBBP) or associated with poor outcome (PTEN, MYT1L) in
the human disease. Strikingly, these candidate genes were enriched for transcription factors (p=2x10-5), the majority
of which (6/7; Crebbp, Myt1L, Nfia, Nfib, Tead1 and Tgif2) were linked within a single regulatory network enriched for
genes associated with a differentiated neuronal phenotype. Furthermore, activity of this network varied significantly
between the human subgroups, was associated with metastatic disease, and predicted poor survival specifically
within the SHH subgroup of tumours. Igf2, previously implicated in medulloblastoma, was the most differentially
expressed gene in murine tumours with network perturbation, and network activity in both mouse and human
tumours was characterised by enrichment for multiple gene-sets indicating increased cell proliferation, IGF
signalling, MYC target upregulation, and decreased neuronal differentiation.
Conclusions: Collectively, our data support a model of medulloblastoma development in SB-mutagenised Ptch+/-
mice which involves disruption of a novel transcription factor network leading to Igf2 upregulation, proliferation of
GNPs, and tumour formation. Moreover, our results identify rational therapeutic targets for SHH subgroup tumours,
alongside prognostic biomarkers for the identification of poor-risk SHH patients.
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Medulloblastoma (MB) is the most common malignant
brain tumour of childhood, accounting for around 10%
of paediatric cancer deaths. Despite recent therapeutic
advances, up to 40% of patients still die from their dis-
ease and cure is often associated with disabling therapy-
related effects in later life. New therapeutic approaches
based on improved biological understanding of the dis-
ease will be essential to improve outcomes, through
strategies such as the delivery of risk-adapted therapies
guided by molecular prognostic biomarkers, and the
stratified use of molecularly-targeted agents (reviewed
in [1]).
Four major molecular subtypes of medulloblastoma
with distinct biological, clinical and pathological features
are now recognised, and this subgrouping is beginning
to have clinical impact [1-3]. WNT subgroup tumours
(~15% of total) are characterised by activation of the
wnt/wingless pathway through CTNNB1 mutations, and
appear to originate from progenitor cells derived from
the dorsal brain stem [4]. Patients with WNT-associated
tumours have a favourable prognosis and will receive re-
duced therapies in forthcoming international clinical tri-
als [1,5,6]. The SHH subgroup (~25% of total) is defined
by activation of the sonic hedgehog signalling pathway,
and mutations in SHH pathway genes (e.g. PTCH1,
SUFU) arise in a significant subset [2,3]. All evidence
suggests that these tumours originate from cerebellar
granule neuron precursors (cGNPs) within the external
granular layer of the developing cerebellum (reviewed in
[7]) or cochlear nuclei of the brainstem [8]. SHH tu-
mours are associated with an intermediate prognosis.
Early clinical trials of SHH pathway inhibitors are under-
way, although acquired resistance has been reported [9]
and tumours with downstream pathway mutations (e.g.
GLI2, SUFU) are predicted to be insensitive to their
action [10]. Group 3 and 4 tumours are more heteroge-
neous and show overlapping molecular features such as
frequent chromosome 17 defects. However, Group 3
tumours (~25% of total) have been associated with high-
risk features, such as MYC gene amplification and large-
cell/anaplastic (LCA) pathology, and a poor prognosis [2].
Recent genome-wide studies have further underlined
the complexity of MB; heterogeneous mutations tar-
geting processes including histone methylation and
chromatin remodelling have been discovered, but these
typically describe limited subsets of tumours and few
additional recurrent mutations targeting specific genes
and/or pathways have been identified [11-15]. Critical
genes therefore remain to be uncovered in all MB sub-
groups and there is a growing need to identify low-
frequency alterations which drive disease progression,
distinguish these from passenger mutations, and deter-
mine their mechanisms of action and clinical significance.Primary tumour data alone may not be sufficient to
achieve these goals.
A number of murine MB models have been created
allowing comparative analyses (reviewed in [16]), inclu-
ding models which recapitulate WNT [4] and Group 3
[17,18] tumours. However, the most widely studied
mouse model is a knockout of the Shh transmembrane
receptor, Ptch [19], which mimics SHH subgroup tu-
mours. Ptch+/- heterozygotes develop MBs at a fre-
quency which is significantly influenced by genetic
background [20]. Sleeping Beauty (SB) murine mutage-
nesis [21,22], coupled to statistical analysis of insertion
site distribution [23,24], has emerged as a powerful
method to identify genes involved in a wide variety of
human cancers [24-29]. Recently the SB11 transposase
[22] driven by the Math1 promoter has been used to
mutagenise developing neuronal tissues in both the
Ptch+/- and p53 loss-of-function models of MB [30]. This
identified a large number of candidate genes potentially
involved in MB progression, and demonstrated that the
genetic events observed in metastases show limited over-
lap with those in matched primary tumours, supporting a
bicompartmental genetic model of metastatic disease
[30,31].
Here, we report the application of whole-body SB mu-
tagenesis [26] to the Ptch+/- tumour model, and the
identification of 17 genes associated with enhanced me-
dulloblastoma formation. We show that these genes are
enriched for neuronal transcription factors defining a
novel gene network which, when mutagenised by SB, is
associated with increased cell proliferation and reduced
neuronal differentiation. Significantly, increased expres-
sion of Igf2, a gene known to be essential for tumour
formation in the Ptch+/- model, is associated with inser-
tional mutations within this network. Moreover, we
show that in human disease, network activity predicts
poor survival specifically within the SHH tumour sub-
group. Together, these findings provide important novel
insights into the molecular mechanisms of medulloblas-
toma pathogenesis, and identify exploitable therapeutic
targets and prognostic biomarkers for development to-
wards improved therapy.
Results
The incidence of MB but not RMS is enhanced in
mutagenised Ptch+/- mice
A total of 243 mutagenised Ptch+/- animals (Ptch+/-;
SB11+/-;T2Onc+/-) and 195 control littermates were aged
for up to 15 months and monitored for tumour develop-
ment. Mortality in mutagenised Ptch+/- animals was
approximately 90% after 1 year, significantly higher than in
the predisposition only (Ptch+/-;T2Onc+/-) or transposition
only (T2Onc+/-;SB11+/-) control genotypes (Figure 1a
and Additional file 1: Table S1). Approximately ~28% of
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Figure 1 Mortality in experimental/control cohorts and tumour pathology. a-c. Kaplan Meier survival curves. All p-values are from log-rank
tests. a. Mortality due to all causes in experimental cohort and controls. b. Medulloblastoma (MB) arising from cerebellum (C). Scale bar = 500 μm.
c. High resolution image showing typical cytomorphology of small, polygonal or slightly elongated cells. Perivascular pseudorosetting and
occasional necrotic foci were also seen in some tumours. Scale bar = 50 μm. d. Mortality due to medulloblastoma alone. The difference
between predisposition and transposition controls was not significant (p=0.118). e. Typical appearance of RMS consisting of variable numbers
of small, round mitotically active cells together with large more well-differentiated rhabdomyoblasts arranged in interlacing fascicles. Scale bar =
200 μm. f. High resolution image showing large rhabdomyoblasts with characteristic cross-striations, accompanied by smaller less well differentiated
cells. Scale bar = 50 μm. g. Mortality due to RMS alone. h. Hepatocellular adenoma containing mixed pattern (micro- and macrovesicular) steatosis and
leukaemic infiltration. Scale bar = 50 μm. i. Low power view of a well demarcated hepatocellular carcinoma with leukaemic infiltration (T=tumour,
L=liver parenchyma). Scale bar = 500 μm. j. High resolution image of hepatocellular carcinoma showing tumour cells (right-hand side of image) with
eosinophilic cytoplasmic inclusions. Scale bar = 50 μm. All sections are stained with Haematoxylin and Eosin.
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months succumbed to haematological neoplasms, which
usually presented as large thoracic tumours and/or
hepatosplenomegaly. A low frequency of parenchymal
brain lesions consistent with glial tumours (2%) was also
observed. These malignancies occurred at comparable fre-
quencies within the transposition controls, have previously
been reported using the same transposase/transposon
combination [26,29], and are not analysed further here.
Despite this mutagen-specific burden, significant mor-
tality within mutagenised Ptch+/- animals was related to
the Ptch genotype. Large exophytic and/or invasive MBs
(Figure 1b and c) developed in ~23% of mutagenised
Ptch+/- animals aged for over 6 months, with no macro-
scopic meningeal masses being observed (typical of the
Ptch model [19]). Tumours with indistinguishable path-
ology were observed in the predisposition controls but
at a much lower frequency (6%), with survival analysis
providing clear evidence that SB mutagenesis enhanced
the predisposition of Ptch+/- mice to MB (p<0.0001,
Figure 1d). Slow growing and locally invasive rhabdo-
myosarcomas (RMSs), also typical of the Ptch+/- model
[32], developed in ~22% of experimental animals aged
over 6 months (Figure 1e and f). However, mutagenesis
did not significantly alter RMS related mortality relative
to predisposition controls (Figure 1g, p=0.31). Finally,
multiple liver tumours (Figure 1h-j), morphologically
similar to those generated using a conditional SB11
screen for hepatocellular carcinoma [27], were observed
in 19 mutagenised Ptch+/- mice but not in predispos-
ition controls. Although not previously reported in
whole body SB mutagenesis screens, liver tumours were
also observed at low frequency in transposition only
controls (Additional file 1: Table S1), suggesting that
they can be induced by SB mutagenesis alone.
SB insertions target neuronal transcription factors
To identify genes responsible for the impact of mutagen-
esis upon MB incidence, transposon insertion sites
within MBs and control cerebellar tissues were reco-
vered using Splinkerette PCR, sequenced, and their dis-
tribution analysed using Gaussian kernel convolution
(GKC [23]) to identify common insertion sites (CISs, see
Methods). A total of 17 genes were identified within 20
CISs recovered [median p-value = 0.008 (Table 1)]. The
majority were also recovered using Monte Carlo simula-
tion analysis [24], and these are highlighted in bold in
Table 1. Three of the CISs target known tumourigenic
genes (Crebbp, Nfib and Pten), mutations within or-
thologs of two (Crebbp and Pten) are somatically mutated
at low frequency in human MB [11,33], and six (Crebbp,
Nfia, Nfib, Pten, Sfi1, and Tead1) have recently been iden-
tified as MB CISs in a tissue-specific mutagenesis screen
[30]. Strikingly, ontological analysis established that six ofthe 17 CIS genes have transcription factor activity (Nfia,
Tead1,Tgif2, Nfib, Myt1l and L3mbtl4), a highly significant
excess relative to expectation (FDR corrected p-value =
2×10-5). Furthermore, seven genes (Tgif2, Pten, Nfia, Nfib,
Myt1l, Slit3 and Fgf13) are implicated in neuronal
biological processes. In contrast, only three genic CISs
were identified in control tissue, all with modest p-values
(0.01-0.05, Table 1). All of these observations are consistent
with insertional mutations at CISs contributing to in-
creased penetrance of the tumour phenotype. As all SB
insertions within Tgif2 mapped to a single ~4 kb intron,
these were analysed in detail using both genomic DNA
and cDNA templates. This both validated our sequence
data and confirmed the inferred upregulation of this gene
by SB insertion (Additional file 2: Figure S1).
Association of CIS genes with survival and focal copy
number alterations
To investigate the association between CIS gene expression
and survival, log-rank (Mantel-Cox) tests were performed
on median split microarray expression data from human
tumours [35]. Reduced expression of two genes, PTEN
(a tumour suppressor previously implicated in MB) and
MYT1L, was associated with poor outcome (Figure 2). This
is consistent with the inferred mode of action of the SB
insertions that target these genes (Table 1). Furthermore, the
association of MYT1L expression with survival remained
significant within a Cox-regression model incorporating
high-risk clinical features using the data from Cho, Tsherniak
et al [35], even after exclusion of the good prognosis WNT
subgroup (p=0.011, see Additional file 3: Table S2).
To investigate the relationship between CIS genes and re-
gions of chromosomal loss or gain defined within primary
tumours [35,36], a GISTIC analysis was also performed [37]:
PTEN maps within a well-established region of common
chromosomal loss on 10q associated with SHH tumours
[38], and both NFIB and TMEM45B were found to be
present within peak regions of localised copy number gain
(Additional file 4: Figure S2). While this is consistent with
the mode of action inferred for PTEN and NFIB, the mode
of action of TMEM45B remains unclear from insert data
alone (Table 1).
CIS genes are differentially expressed in MB clinico-
genetic subgroups
To establish whether the CIS genes are relevant specifically
to the SHH subgroup of tumours, we used published data
sets [38,39] to compare expression of human orthologs in
SHH subgroup tumours with expression in all other sub-
groups. Of the 17 CIS genes, 9 show significant differential
expression when SHH subgroup tumours are compared to
all others (including MYT1L and PTEN discussed above),
and 15 show differential expression in one or more
clinicogenetic subgroups (Table 2). However, only two
Table 1 Common Insertion Sites (CISs) in Medulloblastomas and Cerebellum Controls
Gene Chr CIS width N I GKC p-value Other genes Inferred MOA CGC MB- Mut MB- CIS
A. Medulloblastomas
Nfia 4 28.6 20 27 <1E-14 - Loss - - Ptch
Atxn2 5 25 6 6 <1E-14 - ? - - -
Tead1 7 19.1 6 7 3.9E-14 - Gain - - Ptch
Tgif2 2 0.8 3 4 0.0006 - Gain - - -
Crebbp 16 37.1 5 5 0.0009 - Loss S Y Ptch
Dscr3 16 18.3 5 6 0.0009 - Loss - - -
CIS13:72336914 13 44.3 5 6 0.0042 n/a n/a n/a n/a n/a
Pten* 19 50.2 4 5 0.0046 - Loss S/G Y Both
Itgbl1 14 43.4 5 5 0.0062 Fgf14 ? - - -
Nfib 4 24.7 7 9 0.0071 - Gain S - Ptch
Myt1l 12 67.2 8 10 0.0089 Pxdn,Tpo,Sntg2 Loss - - -
Ankrd5 2 1071.3 8 15 0.0092 Plcb4, Pak7,Snap25 ? - - -
Slit3 11 494.3 8 12 0.012 - Loss - - -
Tmem45b 9 58.4 4 5 0.019 - ? - - -
Sfi1 11 51 5 6 0.021 - Loss - - Both
CIS15:70979306 15 20.3 4 4 0.028 n/a n/a n/a n/a n/a
Fgf13 X 23.5 3 4 0.026 - Gain - - -
CIS3:147532546 3 140.5 4 7 0.043 n/a n/a n/a n/a n/a
L3mbtl4 17 221.6 7 7 0.043 Tmem200c Loss - - -
Adcy5 16 127.1 4 6 0.044 Ptblb Loss - - -
B. Cerebellum controls
Faf1 4 41.7 4 4 0.01 - ?
l7Rn6 7 10 3 3 0.018 Ccdc81 ?
CIS6:31346217_240k 6 844 6 8 0.045 n/a n/a
Ric3 7 99 4 4 0.035 Tub ?
CIS9:68415409_240k 9 1738 9 11 0.016 n/a n/a
Genes associated with CISs, the chromosomes to which they map, and the genomic extent of each CIS are shown. GKC p-values are from the Genome Kernel
Convolution analysis (see Methods). The number of tumours (N) and T2Onc insertions (I) which define each GKC CIS, together with other genes within the CIS
interval, are also shown. The position and orientation of SB insertions can be used to infer the mode of action (MOA) of insertion (e.g. [28]). Most of the CISs have
insertions distributed throughout the genes they identify, and in both orientations, suggesting loss of function (Loss). Both of the CIS genes which have proven
tumour suppressor activity (Pten and Crebbp) show this pattern. An excess of inserts in the 5’ end of a gene, and in a +ve orientation with respect to transcription,
implies upregulation of expression (Gain) through SB enhancer function [34]. CGC – Genes known to cause cancer due to somatic (S) or germline (G) mutations
from the Cancer Genome Census (http://www.sanger.ac.uk/genetics/CGP/Census/). MB-Mut – Somatic mutations previously identified in MB [11,12,14,15]. MB-CIS
– previously identified as an MB CIS [30] in either the Ptch model (Ptch) or the Ptch and p53 model (both). *Pten, was also identified as a CIS within
haematological tumours (data not shown) but is included here as it is a known MB gene. For details, see Methods.
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the SHH subgroup alone. Some show marked differential ex-
pression in a single non-SHH subgroup, such as NFIA (Group
3 tumours) and FGF13 (Group 4 tumours), or in more than
one subgroup (e.g. TGIF2 and MYT1L), suggesting that these
genes may be relevant to MB in general. We also investigated
expression with respect to the presence/absence of metastatic
disease, and 7 genes show a significant association, most
notably genes with extreme expression values in Group 3 and
4 tumours where metastatic disease is common (Table 2).
For 13 genes, a comparison of expression in human
tumours and normal cerebellum was also possible (usingdata from Cho, Tsherniak et al. [35]) and a total of 10
genes show significantly different expression between
cerebellum and either SHH subgroup tumours alone or
all tumours (Additional file 5: Table S3), consistent with
dysregulation of expression during tumorigenesis. Fur-
thermore, the direction of expression change observed is
generally consistent with the predicted mode of action
of each CIS. For instance, expression levels of FGF13,
NFIB, TEAD1 and TGIF2 are all increased versus normal
cerebellum whilst expression of MYT1L, SFI1, and SLIT3
is appropriately reduced (Table S2) in line with the in-
ferred mechanism of action (Table 1).
a b
Figure 2 Expression of MYT1L and PTEN correlates with
survival. Kaplan Meier curves showing survival in high and low
expressing groups in data of [35] split by median of expression in all
MB regardless of subtype. a. MYT1L, b. PTEN. Numbers at risk and
log-rank test p-values are shown.
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in human MBs
The significant enrichment for transcription factor (TF)
activity within the MB CIS genes raised the possibility
that they could be present within co-ordinated signalling
or developmental pathways. ARACNE [40,41] is a me-
thod which uses gene-gene co-regulation measures, and
elimination of indirect relationships, to infer TF-target
interactions within expression data. It has successfully
been used to identify novel oncogenes in expression
datasets from glioma [42] and acute lymphoblastic leu-
kaemia [43]. We used ARACNE to infer regulatory net-
works within publicly available MB gene expression data
([38,39] see Methods). Strikingly, seven CIS genes,
including four of the five CISs with the highest GKC p-
values, were linked within a single network either dir-
ectly or via nearest neighbours (Figure 3). This cluster
of CIS nodes is highly significant (p=0.006 using 1000
randomly re-sampled networks) and consists of 6 genes
with transcription factor/cofactor activity (CREBBP, MY
T1L, NFIA, NFIB, TEAD1 and TGIF2) and one neuronal
growth factor (FGF13). Gene ontology analysis (see
Methods) established that the extended network is
enriched both for transcription factors/regulators
(p=0.0026/0.0035, Additional file 6: Table S4, yellow in
Figure 3) and for genes with ontologies relating to cel-
lular components of differentiated neurons (p=0.019-
0.0042, Additional file 6: Table S4, green in Figure 3).
This suggests that the network consists primarily of
neuronal transcription factors and their targets.
To investigate the relative activity of genes within
these enriched ontologies in human tumours, expression
heatmaps of CIS genes, transcription factors, and neuronal
genes within the network were generated (Figure 4a).
There are clear expression differences between clinicoge-
netic subgroups, consistent both with the ANOVA analysis
of CIS gene expression across subgroups (Table 2) andwith the presence of genes previously shown to be highly
expressed in Group 3 and 4 tumours (e.g. NEUROD2,
GABBR2 [38]). However, most striking are the neuronal
genes which include neurotransmitter receptors and syn-
aptic scaffold/matrix proteins, the vast majority of which
show low expression in the SHH and WNT tumours.
Four of the seven networked CIS genes have recently
been identified as MB CISs in a tissue-specific SB muta-
genesis screen of primary tumours generated using the
Ptch model (Crebbp, Nfia, Nfib and Tead1 [30]), and
orthologs of a further three genes within our network
(Dip2c, Edil3 and Erbb4) were identified as MB CISs in
the same screen. Strikingly, with the exception of Tead1,
both alleles of all of these genes were targeted by inserts
in primary tumours in this screen [30], indicative of key
tumour promoting events. We therefore analysed the
distribution of all 17 biallelic events identified in this
tissue-specific study and found them to be significantly
enriched within our network (6/90, 7%) compared to
outside our network (11/5823, 0.19%; Fisher’s Exact
Test p <0.00001). This provides evidence that the TF
network identified here was also targeted in an inde-
pendent SB screen.
Network activity correlates with advanced disease and
survival in SHH tumours
To assess network activity within human tumour datasets
further, we generated a single “metagene” metric to sum-
marise the expression of CIS network genes. The expres-
sion of each gene was signed according to direction of
correlation with other CIS genes, such that a single score
reflected the unified action of all genes (see Additional
file 7). As a result, the expression of genes where CISs are
inferred to cause loss of function was positively correlated
with metagene score (e.g.MYT1L), whereas the expression
of genes where CISs are inferred to cause gain of function
(e.g. TGIF2, Additional file 2: Figure S1) was negatively
correlated. Metagene activity was then investigated with
respect to MB subgroups and clinical features. As
expected from the expression heatmaps (Figure 4a), the
activity of the network metagene differs significantly be-
tween MB clinicogenetic subgroups (F = 62.8 p<0.0001
Figure 4b), with the highest network activity being ob-
served in Group 4 tumours. Metagene activity is also
higher in tumours presenting with metastatic disease
when compared to those that do not (bootstrapped t =
2.388; p<0.013 Figure 4c). This is likely to reflect the high
metagene expression in Group 4 tumours where metasta-
ses are frequently observed. A subgroup specific analysis
of available expression data which has associated survival
information [35], however, showed that network activity
correlates significantly with survival in SHH subgroup
tumours (log-rank 8.03; p <0.005, Figure 4d), but not in
other subgroups (data not shown).
Table 2 CIS gene expression according to clinicogenetic groups and presence of metastatic disease
Clinicogenetic groups Metastatic disease
SHH v Other Subgroups WNT (N=15) SHH (N=24) Group 3 (N=24) Group 4 (N=48) Mets (N=32) No Mets (n=75)
Mean SHH Mean others t p-val Mean SE Mean SE Mean SE Mean SE p-val Mean SE Mean SE p-val
NFIA 22497_at 11.25 10.80 −1.31 11.41 ± 0.18 11.25 ± 0.30 9.44 ± 0.42 11.32 ± 0.16 ** 10.78 ± 0.32 11.03 ± 0.15
ATXN2 202622_s_at 7.41 7.60 2.00 7.50 ± 0.11 7.41 ± 0.08 7.36. ± 0.11 7.75 ± 0.06 ** 7.68 ± 0.08 7.47 ± 0.05 *
TEAD1 224955_at 10.80 9.85 −6.34 ** 11.10 ± 0.12 10.80 ± 0.12 10.13 ± 0.15 9.33 ± 0.07 ** 9.68 ± 0.13 10.11 ± 0.11 *
TGIF2 216262_s_at 7.61 5.02 −8.98 *** 7.75 ± 0.10 7.61 ± 0.23 5.48 ± 0.28 3.97 ± 0.10 ** 4.46 ± 0.22 5.88 ± 0.22 ***
CREBBP 202160_at 9.93 9.80 −0.85 9.95 ± 0.10 9.93 ± 0.10 9.13 ± 0.32 10.09 ± 0.07 ** 9.76 ± 0.13 9.82 ± 0.12
DSCR3 203635_at 7.08 6.78 −3.19 ** 6.84 ± 0.18 7.08 ± 0.08 6.69 ± 0.09 6.80 ± 0.06 ** 6.82 ± 0.08 6.82 ± 0.06
PTEN 225363_at 10.31 11.12 4.63 *** 11.16 ± 0.20 10.31 ± 0.15 10.12 ± 0.15 11.62 ± 0.06 ** 11.03 ± 0.14 10.94 ± 0.10
ITGBL1 214927_at 6.49 3.90 −4.47 *** 4.27 ± 0.56 6.49 ± 0.55 3.16 ± 0.25 4.16 ± 0.25 ** 3.91 ± 0.33 4.85 ± 0.27 *
NFIB 209290_s_at 12.92 12.67 −0.66 10.46 ± 0.48 12.92 ± 0.32 12.18 ± 0.38 13.58 ± 0.09 ** 12.81 ± 0.28 12.85 ± 0.16
MYT1L 210016_at 8.27 10.24 2.80 ** 6.06 ± 0.70 8.27 ± 0.64 9.20 ± 0.43 12.02 ± 0.11 ** 11.28 ± 0.22 9.41 ± 0.36 **
ANKRD5 220144_s_at 4.63 4.75 0.54 4.51 ± 0.28 4.63 ± 0.19 5.46 ± 0.21 4.46 ± 0.10 ** 4.65 ± 0.16 4.77 ± 0.11
SLIT3 203813_s_at 3.01 2.98 −0.17 2.90 ± 0.09 3.01 ± 0.14 2.82 ± 0.05 3.09 ± 0.10 2.98 ± 0.10 2.94 ± 0.06
TMEM45B 226226_at 2.37 2.44 1.57 2.34 ± 0.04 2.37 ± 0.04 2.52 ± 0.04 2.44 ± 0.03 * 2.45 ± 0.03 2.44 ± 0.02
SFI1 36545_s_ar 5.96 5.19 −2.68 5.74 ± 0.24 5.96 ± 0.25 4.42 ± 0.23 5.42 ± 0.19 ** 5.24 ± 0.20 5.36 ± 0.16
FGF13 205110_s_at 5.88 8.10 6.66 * 5.33 ± 0.86 5.88 ± 0.54 6.81 ± 0.49 9.58 ± 0.16 ** 8.73 ± 0.39 7.01 ± 0.32 **
L3MBTL4 228557_at 6.85 3.73 −7.43 *** 4.28 ± 0.28 6.85 ± 0.40 4.82 ± 0.22 3.01 ± 0.10 ** 3.76 ± 0.21 4.59 ± 0.24 *
ADCY5 228182_at 3.50 3.70 0.66 *** 3.52 ± 0.27 3.50 ± 0.27 2.73 ± 0.16 4.25 ± 0.21 ** 3.65 ± 0.22 3.60 ± 0.16
Genes and associated Affymetrix probe IDs are shown. All values are mean log2 expression levels from [38] and [39]. Standard errors (SE) are shown. SHH v Other Subgroups, and presence/absence of metastatic
disease, were analysed using t-tests. Clinicogenetic groups [2] were analysed using ANOVA. *p<0.05, **p<0.01, ***p<0.001.
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Figure 3 A neuronally enriched transcription factor network is defined by MB CIS genes. MB CIS genes (enlarged) linked via nearest
neighbours are shown. The topological arrangement of connected CIS nodes is highly significant (p<0.006) as the average minimum path
distance between the 7 CISs is lower than in 994/1000 randomly resampled networks. All network edges are supported with a bootstrapped p-
value of <1x10-8. Genes identified as biallelically mutated MB CISs by Wu et al. [30] are shown as diamonds. Genes with transcription regulator
activity (GO ID 30528) are shown in yellow. Genes with enriched ontologies associated with differentiated neurons (GO IDs 45202, 44456, 45211,
43005, 43198) are shown in green. Other genes with a known role in neuronal development are shown with a green border. For details of
network construction, see Additional file 7. For details of enriched ontologies see Additional file 6: Table S4.
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identifies Igf2 as a key network associated gene
To identify specific genes whose expression might be al-
tered by network mutations, we generated murine expres-
sion data using Illumina bead arrays (see Methods) from
30 SB induced tumours, 6 non-mutagenised tumours from
Ptch+/- animals, and 6 normal cerebella. We first validatedthe mutagenised murine model in terms of gene expres-
sion as follows: Four metagenes were generated from hu-
man tumour expression data using NMF (see Methods) to
define the four MB biological subgroups. These metagenes
were then projected across the mouse tumour data using
all available orthologous probes (Figure 5a), and the sub-
group identity of the mouse tumours was then tested with
Figure 4 Network activity correlates with tumour subgroup, metastasis and survival. a. Gene expression heatmaps of CIS genes and
network genes with enriched ontologies in all 4 clinicogenetic subgroups are shown. Where more than one probe per gene was present in the
network, the probe with the highest mean expression level across all samples is shown. b. Box and whisker plot showing log of metagene
expression in MB clinicogenetic subgroups. ANOVA p-value is shown. Boxes represent the 25th to 75th percentile, with median values shown as
solid lines. Whiskers represent 95th percentile, and outliers are shown individually. c. Log of metagene expression in tumours with metastases and
those without. T-test p-value is shown. d. Kaplan Meier curve of SHH subgroup tumours relative to Metagene score.
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scores for the human data as the training set and the
mouse tumours as the test set. All human tumours were
trained correctly with zero errors. The mouse SB tumours
were also correctly predicted to be SHH tumours in 29/30
(96%) of cases (Figure 5b) and 6/6 (100%) of non-
transposon PTCH MB controls, establishing that gene ex-
pression in SB induced mouse tumours is similar to ex-
pression in human SHH tumours.
We then looked for genes differentially expressed be-
tween tumours with hits in CIS network genes and
tumours with no hits in these genes. This identified the
Insulin-like growth factor 2 (Igf2) as the most differentially
expressed gene with a mean fold change of 3.58 (p=0.002,
Additional file 8: Table S5). To validate the association
between network insertions and Igf2 expression, wequantified Igf2 expression in all of our SB-induced MB tu-
mours for which RNA was available using Real Time PCR
(See Methods). This confirmed that Igf2 was expressed at
a significantly higher level in tumours with one or more
insertions in a network CIS gene, than in tumours with no
insertion in a network CIS gene (p<0.0001, Figure 5c).
Furthermore, we also established that tumours with hits in
Nfia, the CIS gene most frequently affected by SB inser-
tion, expressed Igf2 at higher levels than network tumours
with no insert in Nfia (Figure 5c).
CIS related Network activity is associated with
proliferation and reduced differentiation
Finally, to gain insight into biological processes which
may be affected by the network, we also performed a
Gene Set Enrichment Analysis (GSEA) which uses gene
Figure 5 Ptch+/- MBs are SHH subgroup tumours and Igf2 is a
key network associated gene. a-b. Projection of four sub-group
specific metagenes derived from 108 human primary MB expression
profiles (Training Set) onto MB mouse model expression profiles
(Test Set) using Non-negative Matrix Factorisation (NMF). a.
Heatmaps showing expression of metagenes across human tumours
(training; left panel) and expression of metagenes across murine
tumours (test; right panel). b. Pseudo-plot of NMF projections
coloured according to confident MB sub-group classification of
murine tumours using metagene expression values. This
unsupervised analysis shows that the majority of Ptch mouse model
samples recapitulate the expression profiles of primary SHH MB. c.
Box and whisker plots showing relative Igf2 expression assayed by
Real Time PCR (for details, see Methods): Left Panel - tumours with
inserts in 1 or more network CIS gene versus tumours with no inserts;
Right Panel - Igf2 expression in tumours with 1 or more insertions in
Nfia versus all other tumours with inserts in at least 1 network CIS gene.
Boxes represent the 25th to 75th percentile, with median values shown
as solid lines. Whiskers represent 95th percentile, and outliers are shown
individually. d-e. GSEA plots for human tumours ranked by metagene
score (left panels) and mouse tumours ranked by fold change of
expression in tumours with network hits compared to predisposition
control MBs not exposed to mutagenesis (right panels). ES-Enrichment
Score, RM-Ranked list Metric. d. Lein_Neuron_Markers. Human NES=2.15
p<0.001, Mouse NES=-2.24 p<0.001. e. KEGG_Ribosome. Human
NES=-3.00 p<0.001, Mouse NES=2.59 p<0.001.
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[44]. This was performed both in mouse tumours (rank-
ing genes by fold change of expression in SB-induced
tumours with network hits compared to Ptch+/- MBs
not exposed to mutagenesis) and in primary human
MBs (ranking by association with metagene score).
GSEA revealed a broad picture of increased cell prolif-
eration and reduced differentiation associated with net-
work hits in mice and low network metagene activity in
human tumours (the concordant gene expression
pattern), as demonstrated by significant enrichment of
multiple genesets (see Additional file 9: Table S6). For
instance, genesets indicative of neuronal differentiation,
such as “Cahoy_Neuronal” and “Lein_Neuron_Markers”,
are significantly enriched in human MBs with high
metagene expression and in MBs from murine PTCH
controls with no transposition (e.g. Figure 5d). A similar
effect is seen for genesets describing genes containing
CREB and cAMP responsive elements (e.g. Additional
file 10: Figure S3A). In contrast, genesets denoting pro-
liferation and elevated cell growth are significantly
enriched in human MB with low network metagene ac-
tivity and mouse PTCH MBs with CIS network hits.
These include genesets linked to mitosis and cell cycle,
MYC targets (Additional file 10: Figure S3B), and ribo-
some biogenesis (Figure 5e).
Consistent with increased Igf2 expression in MBs from
mice with network hits, enrichment of IGF-related
genesets is also observed in human and mouse tumours;
e.g. enrichment of Pacher_Targets_of_IGF1_and_IGF2_
up in mouse tumours with network hits (Additional file
10: Figure S3C), and of Boudoukha_Bound_by_IGF2BP2
in human tumours with a low Metagene score (Additional
file 10: Figure S3D). In addition, the genesets Lee_Targets_
of PTCH1_and_SUFU “_up” and “_dn”, indicative of SHH
dependent murine tumorigenesis [45], show consistent
differential enrichment; upregulated targets are enriched
in mouse network tumours and human tumours with a
low Metagene score (Additional file 10: Figure S3E), and
downregulated targets are enriched in mouse tumours
with no mutagenesis and human tumours with a high
Metagene score (Additional file 10: Figure S3F). Collect-
ively, the broad concordance of human and murine
datasets indicates conservation of CIS mutational function
across species, and substantiates the concerted action of
CIS network genes as a tumourigenic process promoting
cell proliferation and inhibiting neuronal differentiation.
Discussion
We have shown that whole body SB mutagenesis of
Ptch+/- mice significantly enhances MB frequency with-
out affecting latency, and does not induce these tumours
in wild type mice. The majority of candidate genes
identified have either been implicated in neuronal
Figure 6 Integrated summary of metagene expression,
associated clinical features, and GSEA. The schematic relationship
between mouse and human tumours in terms of network genes is
shown in the top panel. Expression heatmaps showing the network
metagene and CIS genes in 108 MBs by subgroup [38,39], together
with the incidence of metastatic disease, are shown in the middle
panel. For all genes, data from the most highly expressed Affymetrix
probe are shown. In the metastases track, red = presence, green =
absence, grey = no data. In the histological subtype track, magenta =
classic, green = desmoplasia, blue = LCA. A schematic of key
processes relevant to tumour biology identified by GSEA is shown
in the bottom panel. For details of GSEA, see text and Additional
file 9: Table S6.
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been linked to SHH signalling, or have been shown to
be mutated in SHH subgroup tumours in humans. Fur-
thermore, we found that one gene identified from our
screen, MYT1L, is of prognostic value within a multi-
variate analysis of human MB survival data. These genes,
therefore, warrant individual assessment as potential
therapeutic targets and/or biomarkers for the improved
stratification and treatment of medulloblastoma.
Notably, 7 of the genes (6 transcription factors/cofac-
tors and 1 growth factor) show significant associations
with each other within a novel MB expression network,
implying a previously unidentified functional relation-
ship which does not map to established canonical path-
ways. This network is enriched for transcriptional
regulators and genes with neuronal ontologies, and links
genes with roles in stem cell/neuron migration, neurite
growth and neuronal cell cycle progression, to genes
which encode structural and functional elements of ma-
ture neurons (See Additional file 11: Table S7 for known
gene functions). This suggests that the network com-
prises transcription factors involved in the proliferation
and differentiation of cGNPs, the cell of origin for SHH
MB [7], and their targets. Interestingly, lineage commit-
ment to cGNP identity is a pre-requisite for SHH
tumour development [46,47].
The relationships identified here between murine net-
work activity, metagene activity in human tumour sub-
types, and individual CIS gene expression, are summarised
in Figure 6. This highlights the variable network activity
within SHH tumours and Group 3 tumours, and identifies
CIS genes with similar, or wholly divergent, expression
patterns relative to the metagene. Of these, TGIF2 and
MYT1L are of particular interest as they influence neur-
onal SHH expression and development, respectively: A
conditional Tgif1/Tgif2 double knock-out has recently
been shown to reduce Shh expression in the developing
brain and to recapitulate holoprosencephaly [a human
condition caused by SHH and TGIF1 mutations (OMIM#
142945 and 142946)], while the transcriptional repressor
MYT1L can contribute to the re-programming of human
fibroblasts into neurons [48,49]. As neither gene has been
implicated in MB development to date, both are prime tar-
gets for further investigation.
Importantly, network activity has clinical relevance, as
high activity is associated with advanced disease in all
tumours and low activity is associated with poor survival
specifically in SHH subgroup tumours (Figure 6). These
associations appear incongruous, but the former is likely
due to the high incidence of metastases in Group 4
tumours where network activity is uniformly high. In
contrast, the SHH subgroup-specific association with
outcome may reflect clinically important variation in the
developmental status of individual tumours, andhighlights the potential utility of network activity as a
prognostic biomarker for the prediction of outcome
within the SHH subgroup.
The GSEA analysis in mouse and human tumours
demonstrates very clearly a role for this network in
inhibiting neuronal differentiation and promoting cell
proliferation. Consistent with this, several common
functional pathways were identified in both species of
potential relevance to disease. Of these, the MYC and
IGF-dependent signalling pathways are of particular
interest, the latter having recently been highlighted in an
independent SB screen [30]. Furthermore, our analysis
of gene expression in SB mutagenized mouse tumours
identified Igf2 upregulation as a key output of SB-
induced network perturbation. Igf2 is already known to
be required for MB development in the Ptch+/- model as
no tumours are observed in Igf2 null; Ptch+/- mice [50],
over-expression of Igf2 in Ptch+/- mice increases the fre-
quency of MBs generated by Shh transfection of cerebel-
lar neural progenitors [51], and at the cellular level Igf2
acts synergistically with Shh to increases murine cGNP
cell proliferation 10 fold [52].
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tions converge to inhibit differentiation and upregulate
Igf2. This extends the existing model of MB formation
in SB mutagenised Ptch+/- mice by identifying genes
underpinning the upregulation of Igf2 which leads to the
persistence of Ptch+/--induced cerebellar proliferative le-
sions and progression to MB [53]. Consistent with this
model, several network CIS genes, or genes which they
bind/modulate, have already been implicated in Igf2 ex-
pression or activity, including Tead1 [54], Nfia and Nfib
[55,56], and Crebbp [57]. There is an unmet clinical need
for the development of SHH pathway-independent
targeted therapies for SHH subgroup tumours, particu-
larly in view of the predicted acquired or intrinsic resist-
ance to current SMO inhibitors [9,10]. The implication
of insulin-dependent signalling in human and mouse
SHH tumours strongly support its development as a
therapeutic target for SHH subgroup tumours.
The application of SB mutagenesis to additional mur-
ine MB models [17,18] could identify genes relevant to
other tumour subgroups. However, our results contrast
sharply with a recent Math1 driven tissue-restricted
screen of a more penetrant Ptch+/- model [30] where
tumour latency was reduced from 8 to 2.5 months, a
high frequency of metastases (80%) was observed, and
divergent primary and metastatic insertional mutation
signatures were defined. Notably, we did not observe me-
tastases following whole-body mutagenesis in this study.
These two models are, therefore, not directly comparable
and suggest that penetrance of the tumour predisposition,
and the power of the mutagen, are likely to determine the
nature of genes identified in future screens.
Finally, this is the first time to our knowledge that mu-
tagenesis data from a murine cancer model have been
integrated with human expression networks to explore
biological mechanisms of tumourigenesis. The identifica-
tion of novel and biologically relevant candidate genes
linked within a single expression network, the activity of
which correlates with disease state and survival within
the subgroup of tumours being modelled, illustrates the
utility of this cross-species approach. Clarification of the
interactions between network genes identified here, their
roles in the pathways highlighted by our GSEA analysis,
and establishment of their therapeutic relevance will,
however, require extensive functional analyses of mul-
tiple genes both individually and in concert.
Conclusions
Here, we have used SB mutagenesis to define a novel
neuronal transcription factor network involved in me-
dulloblastoma formation within the Ptch+/- model, and
provide evidence that disruption of this network up-
regulates Igf2, critical for proliferation of GNPs and
tumour formation. Moreover, we have identified rationaltherapeutic targets for SHH subgroup tumours, along-
side prognostic biomarkers for the identification of
poor-risk SHH patients, supporting the further develop-
ment of these findings as a basis for improved and
individualised therapy. Our results also suggest that the
integration of mutagenesis data and expression network
analysis may help to unravel key events in other cancers
which disrupt complex developmental programmes, for
which murine models are available.
Methods
Mice strains
The following strains were used: B6 Ptch1tm1Mps/J mice
[19]; CBA wild type (Charles River laboratories, Margate,
UK); T2Onc line 76 [58] and SB11 Rosa26 [22]. All ani-
mal work adhered to UK Home Office guidelines and
was performed under Project Licence PLL/60/3621. Ani-
mal numbers, together with tumour incidence in each
genotype, are given in Additional file 1: Table S1.
Sample processing, insertion site mapping and CIS
identification
Tumours and other abnormal tissue identified upon post-
mortem examination were collected for histological exam-
ination and DNA/RNA isolation. Insertion sites were
identified using splinkerette PCR [21] coupled to GS-FLX
amplicon sequencing [59] and sequence reads were map-
ped to the mouse genome (NCBI37/mm9) as described
previously [60]. Common insertion sites (CISs) were
identified using Gaussian kernel convolution (GKC)
[23]. The raw p-value of each CIS peak was corrected
for the total number of CIS peaks on the chromosome
to which it maps, with a cut off of p<0.05. Monte Carlo
simulation methods [24] were also used for compara-
tive purposes.
Illumina expression analysis and Real Time PCR
200 ng of each RNA was amplified and biotin labelled
using the Illumina TotalPrep RNA amplification kit
(Applied Biosystems, Foster City, CA. USA). cRNA size
distribution was assessed using an Agilent Bioanalyser.
Approximately 750 ng of each cRNA was hybridised to
the Illumina Mouse8 Reference Array (Illumina, Essex,
UK) according to the manufacturer’s recommended pro-
tocols by the Wellcome Trust Clinical Research Facility
(Edinburgh, UK). Real Time PCR was performed using
the 5’ nuclease assay on the ABI PRISM™ 7700 Sequence
detector (Perkin-Elmer, Applied Biosystems, Foster
City, CA, USA). Oligonucleotides were designed using
Primer Express software (v3.0, PE Biosystems, Foster
City, CA, USA), and were designed to span an intron to
avoid amplification from genomic DNA. Mean Ct
values were normalised against the average expression
of the endogenous control gene β−Actin. Relative gene
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using the control cerebellar RNA which showed the
highest expression level as measured by the Illumina
microarray data. For primer sequences see Additional
file 7.
Bioinformatic Analyses
Expression profiles comprising 119 Affymetrix HGU133p2
arrays were taken from published studies [38,39]. CEL files
were processed using the Bioconductor RMA package
[62]. The ARACNE network was constructed using the
aracne2 standalone software package according to authors
instructions [40]. Ontology analyses were performed using
the Bingo 2.44 Cytoscape plug in [63], with Benjamini and
Hochberg FDR-corrected hypergeometric tests and the
whole annotation set as background. The topological ar-
rangement of 7 network genes was significance tested by
calculating the mean shortest path distance to the nearest
connecting CIS gene and permuting 10,000 times with 7
randomly selected genes in order to create a null
distribution.
GISTIC analyses [37] were performed using the module
provided in Genepattern [64], with Affymetrix SNP Chip .
CEL files [35,36] being processed using the Aroma pack-
age [65] and segmented using the CBS algorithm [66].
GSEA [44] was performed using the standalone package
(www.broadinstitute.org/gsea/) and genesets were taken
from the MsigDB library [67]. NMF (Non-Negative Matrix
Factorisation) was performed using a script adapted from
[68]. All other statistical tests were performed using R
[69]. For further details of procedures and analyses, see
Additional file 7.
Availability of supporting data
Microarray gene expression data from this study have
been deposited in the Gene Expression Omnibus as sub-
mission GSE43994. Insertion site data in the form of
BED files are provided as Additional files 12 and 13.
Additional files
Additional file 1: Table S1. A. Tumours in experimental and control
cohorts. Median age of onset and range of onset is given for common
tumour types. Genotypes: Experimental – Ptch+/-;SB11+/-;T2Onc+/-.
Predisposition - Ptch+/-;T2Onc+/-. Transposition - SB11+/-;T2Onc+/-.
1Parenchymal brain lesions were consistent with gliomas and included
one with pseudopalisading necrosis consistent with glioblastoma
multiforme. 2Morphological and immunohistochemical analysis
established that ~50% of haematological malignancies were precursor
T-cell lymphoblastic lymphomas/leukaemias, ~5% were confirmed
myeloid neoplasms, and the remainder were poorly differentiated
haematological neoplasms, mostly of probable myeloid lineage. 3RMSs
developed most frequently on the hindquarters and lower limbs.
4Adenomas showed mild dysplasia with frequent intralesional steatosis,
although sufficient atypia and eosinophilic cytoplasmic inclusions were
observed in 2 nodules to warrant classification as hepatocellular
carcinoma. All but 2 were identified in animals where other malignancieswere also present (4 RMS, 10 Haematological, 1 with RMS
+Haematological, and 2 unclassified). All animals with liver adenomas
were male, a highly significant bias (p<0.0001). 5Hydrocephalus has
previously been reported in this model [19] B. Transposon Insertions by
sample group. N – number of samples analysed. All inserts – total
number of inserts after initial mapping and filtering. SSIs removed –
Number of Same Site Inserts (present in same dinucleotide in different
samples) removed. STIs removed – Number of Same Tumour Inserts
(multiple inserts present in same CIS from same sample) removed. 1
One tumour did not yield high quality DNA and could not be
used for CIS identification. For details of filtering, see Additional file 7.
Additional file 2: Figure S1. MB T2Onc insertions in Tgif2. A. Genomic
organisation of Tgif2 is shown with orientation and location of T2Onc
insertions indicated, together with PCR amplicons from tumour genomic
DNA using primers specific for T2Onc and Exon 2. An amplicon of the
expected size is obtained from each tumour, confirming that all inserts
defined by the GS-FLX sequencing are present. B. Identification of
chimeric T2Onc/Tgif2 transcripts. The schematic shows the relative
position of primers within T2Onc and Exons 1 and 2 of Tgif2, together
with PCR amplicons obtained from tumour cDNA templates. Top panel –
primers E1 and E2. Tumours with inserts show reduced intensity of the
expected E1-E2 transcript. Middle panel – primers SD to E2. Chimeric
T2Onc/Tgif2 transcripts are observed only in tumours with inserts. Bottom
panel – Gapdh loading control. Approximate size of expected amplicons
is shown in all cases. M – 100 bp ladder, C – no DNA controls. For primer
sequences, see Additional file 7 and Keng et al. [27].
Additional file 3: Table S2. Multivariate analysis of human survival
data. Models used the data from Cho Tsherniak et al. [35] and
incorporated as variables their “high-risk clinical” factor (which
incorporates multiple risk factors including the presence of metastases),
and the presence of LCA pathology. WNT subgroup tumours were
removed as they are known to have a distinct outcome. For MYT1L, low
expression was retained as a significant multivariate factor (Relative
Risk=2.8 p=0.019) alongside LCA (Relative Risk = 2.983 p=0.013). “Clinical
Risk Group” was not significant in combination with Low MYT1L
expression which was preferentially retained in a forward stepwise
model. Likewise, for PTEN, low expression was significantly associated
with increased risk of death (Relative Risk = 2.6 p = 0.031) independent
of LCA pathology (Relative Risk = 3.6 p = 0.003). All models have 1
degree of freedom.
Additional file 4: Figure S2. Combined data from Cho, Tsherniak et al.
[35] and Northcott, Korshunov et al. [36] were analysed. A. Significant
overrepresentation of chromosome 10 loss at the PTEN locus and B.
significant overrepresentation of chromosome 9 and Chromosome 11
gain at the NFIB and TMEM45B loci respectively. Dotted lines indicate
position of centromeres. Upper values in each panel are G-scores, lower
values are q-values. C. SNP array data showing localised gain of TMEM45B.
Approximate cytogenetic positions are given above the schematic, with
Megabase position on chromosome 10 given below it. The region of
gain, although small, includes additional genes with known roles in
cancer (ETS1, FLI1) and neuronal development (PRDM10).
Additional file 5: Table S3. Gene Expression in tumours versus normal
cerebellum. Comparisons are shown between all tumours and normal
cerebellum (left) and between SHH subgroup tumours only and normal
cerebellum (right), using data from Cho, Tsherniak et al. [35]. Genes and
associated Affymetrix probe IDs are shown. AveExpr - mean log2
expression levels, t – t test statistic, P.Value – Raw p-value, adj.P.Val –
p-value adjusted for multiple tests.
Additional file 6: Table S4. Cellular Component and Molecular
Function Ontologies over-represented in Network. P-value correction was
achieved using a Benjamini and Hochberg False Discovery rate of 0.05.
Gene frequencies in the network list and genome are shown. Ontologies
marked with an asterisk are not significantly enriched when CIS genes
are excluded.
Additional file 7: Additional details of sample processing, SB
insertion site mapping, statistical analyses, and PCR primers.
Additional file 8: Table S5. Expression differences in Network v Non-
Network tumours. Genes showing the highest average fold change
Łastowska et al. Acta Neuropathologica Communications 2013, 1:35 Page 14 of 16
http://www.actaneurocomms.org/content/1/1/35between tumours with 1 or more insert in a Network CIS and tumours
with no network insertions are shown, together with Illumina Probe IDs.
All p-values are Student t-tests with 28 degrees of freedom.
Additional file 9: Table S6. Network Enriched Genesets in primary
human MBs and murine tumours. Significantly enriched genesets are
shown separately or combined as an intersection between mouse and
human results. Associated Nominal p-values corrected for multiple
testing, and FDR q-values are also shown. The excel file contains several
pages each referring to one of six MSigDb Libraries C1-C6 (see http://
www.broadinstitute.org/gsea/msigdb/index.jsp). Human tumours were
ranked by metagene score, mouse tumours were ranked by fold change
of expression in tumours with network hits compared to predisposition
control MBs not exposed to mutagenesis. For details, see Methods.
Additional file 10: Figure S3. GSEA plots for human tumours ranked
by metagene score (left panels) and mouse tumours ranked by fold change
of expression in tumours with network hits compared to predisposition
control MBs not exposed to mutagenesis (right panels). ES-Enrichment
Score, RM-Ranked list Metric. A. Human NES=1.37 p=0.003; Mouse NES=-1.62
p=0.005. B. Human NES = -2.33, p<0.001; Mouse NES = 1.80, p<0.001. C.
Human NES = 1.74, p=0.002; Mouse NES = -1.41, p=0.067. D. Human
NES = 1.36, p=0.07; Mouse NES = -1.68, p<0.001. E. Human NES = -2.29,
p<0.001; Mouse NES = 1.77, p = 0.002. F. Human NES = 2.19, p<0.001;
Mouse NES= - 1.68, p=0.002. For details, see Additional file 9: Table S6.
Additional file 11: Table S7. CIS and Network Genes with functions of
potential relevance to MB. Genes implicated in neuronal structure,
neuronal development, cell cycle, apoptosis or cancer are listed together
with relevant citations. A. CIS genes. Network CISs are shown in bold. B.
Other transcriptional regulators and neuronal genes in network (from
Figure 3 and Additional file 6: Table S4).
Additional file 12: SB inserts in medulloblastomas Bed file containing
all SB insertion site information from all medulloblastomas analysed,
mapped against the NCBI37/mm9 genome build.
Additional file 13: SB inserts in controls Bed file containing all SB
insertion site information from all control cerebellar samples
analysed, mapped against the NCBI37/mm9 genome build.
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